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Abstract
An observational correlation between a suspected risk factor and an outcome
does not necessarily imply that interventions on levels of the risk factor
will have a causal impact on the outcome (correlation is not causation). If
genetic variants associated with the risk factor are also associated with the
outcome, then this increases the plausibility that the risk factor is a causal
determinant of the outcome. However, if the genetic variants in the analysis
do not have a specific biological link to the risk factor, then causal claims
can be spurious. We review the Mendelian randomization paradigm for
making causal inferences using genetic variants. We consider monogenic
analysis, in which genetic variants are taken from a single gene region, and
polygenic analysis, which includes variants from multiple regions. We focus
on answering two questions: When can Mendelian randomization be used
to make reliable causal inferences, and when can it be used to make relevant
causal inferences?
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1. INTRODUCTION
A modifiable exposure variable has a causal effect on an outcome if intervening on the value of
the exposure leads to changes in the average value of the outcome (58). For a disease outcome, an
exposure (referred to hereafter as a risk factor) is causal if intervening on the risk factor leads to
changes in disease risk. Questions about causal relationships are fundamental to epidemiological
research—for example, to determine disease etiology, predict the impact of a medical or public
health intervention, guide drug development, advise clinical practice, or counsel on the impact of
lifestyle choices.
The use of genetic variants to address questions about the causal status of risk factors by
assuming that the variants are instrumental variables (IVs; see Section 2.2 for definition) is known
as Mendelian randomization (28, 37). While Mendelian randomization is not the only paradigm
for assessing causal relationships using genetic information, it is the most commonly used, and is
the main focus of this review.
An ongoing development that is changing the way that Mendelian randomization analy-
ses are performed is the increasing availability of summarized data from large consortia (24).
Summarized data comprise beta coefficients and standard errors taken from regression (gener-
ally linear for continuous variables and logistic for binary variables) of the trait of interest on
each genetic variant (22). Beta coefficients represent the average change in the trait per addi-
tional copy of the effect allele. Typically (and ideally for Mendelian randomization), these re-
gression models additionally adjust for genetic principal components of ancestry and sometimes
for age and sex, but not for further variables (11). Several consortia, such as the Global Lipids
Genetics Consortium for lipid fractions (46) and the Coronary Artery Disease Genome Wide
Replication and Meta-Analysis plus The Coronary Artery Disease (CARDIoGRAMplusC4D)
Consortium for coronary heart disease (CHD) (33), have made these association estimates pub-
licly available for download. A collated, queryable database of these associations can be found
at http://www.phenoscanner.medschl.cam.ac.uk (85). Several other sources of these associ-
ations are also available (for example, associations estimated in UK Biobank can be found at
https://sites.google.com/broadinstitute.org/ukbbgwasresults). This has facilitated the imple-
mentation ofMendelian randomization analyses, which can be conducted using these summarized
data, and in particular two-sample Mendelian randomization, in which genetic associations with
the risk factor and with the outcome are obtained from separate data sources (78). Two-sample
Mendelian randomization is attractive because genetic associations with risk factors should be esti-
mated in cohort or cross-sectional studies of healthy individuals (12), whereas genetic associations
with disease outcomes are best estimated in case–control studies.
Even when individual-level data are available, it is often advantageous to use these to calculate
the summarized associations, either to combine them with a summarized data resource to increase
sample size or to consider causal estimates based on the different genetic variants to assess the IV
assumptions (16). The majority of the analyses discussed in this review can be undertaken using
summarized data. Software code for implementing these analyses in R based on the Mendelian-
Randomization package (101) is provided in the Supplemental Appendix.
This review concentrates on answering two questions: First, when can Mendelian randomiza-
tion be used to make reliable causal inferences? And second, when can it be used to make relevant
causal inferences?
2. MONOGENIC ANALYSES: THE SIMPLE CASE
We divide inquiries into causal relationships into two categories: monogenic analyses and poly-
genic analyses. Bymonogenic analyses, wemean investigations into the causal nature of risk factors
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using genetic variants from a single gene region. This contrasts with polygenic analyses, which
include genetic variants from multiple gene regions.
2.1. Example: C-Reactive Protein and Coronary Heart Disease Risk
We introduce the technique of Mendelian randomization and the assumptions required using
an example; technical details of all examples in the review are provided in the Supplemental
Appendix. C-reactive protein (CRP) is an acute phase reactant and part of the body’s inflamma-
tory response mechanism. Observationally, it is correlated with a multitude of traits, including
cardiovascular risk factors and CHD risk (43). However, these observational associations do
not imply that CRP is necessarily a causal risk factor for CHD. It could be that there are
confounders—common determinants of the risk factor and the outcome—that give rise to the
association. Alternatively, it could be that CRP levels increase in response to subclinical CHD, an
example of reverse causation. Before spending millions of dollars developing and then validating
a drug that decreases CRP levels, it would be prudent to first ensure that decreasing CRP levels
will lead to reductions in CHD risk.
Genetic variants in the CRP gene region are associated with CRP levels (where italics indicates
the gene name, and nonitalics indicates the biomarker). For each additional copy of the T allele
for rs1205 (one particular variant in this region), individuals have a CRP level that is lower by an
average of 0.169 standard deviations [95% confidence interval (CI)= 0.153–0.185] (32). However,
the rs1205 variant is not associated with CHD risk, with an odds ratio (OR) of 0.999 (95%
CI= 0.980–1.019) per additional copy of the T allele (33). Subgroups in the population with
different numbers of T alleles and therefore different average levels of CRP do not have different
prevalences of CHD risk. This suggests that decreasing average CRP levels in the population
would not lead to reductions in CHD risk and that CRP is not a cause of CHD risk. By contrast,
genetic associations with CHD risk for variants in the IL6R gene region (61, 63) and the IL1RN
gene region (62) provide evidence that the interleukin-6 and interleukin-1 pathways, respectively,
are implicated in CHD etiology and that these pathways are worthwhile therapeutic targets [as
has now been demonstrated clinically for interleukin-1 (81)].
2.2. Instrumental Variable Assumptions
The risk factors CRP, interleukin-6, and interleukin-1 are excellent candidates for Mendelian
randomization investigations because there are gene regions that have strong and plausibly specific
links with each risk factor: the coding regions for CRP (CRP), interleukin-6 receptor (IL6R), and
interleukin-1 receptor antagonist (IL1RN), respectively. For a genetic variant to provide a reliable
test of the causal status of a risk factor, it should be associated with the risk factor but not with any
confounders of the risk factor–outcome association, nor should it directly influence the outcome
(41, 66). This means that subgroups of the population defined by the genetic variant differ on
average systematically only with respect to the risk factor and any downstream consequences
of the risk factor, and any association of a variant with the outcome is a result of the variant’s
association with the risk factor.
The assumptions for a genetic variant to be an IV are (a) that it is relevant (the average value
of the risk factor depends on the genetic variant), (b) that it has no association with confounders
(the genetic variant is independently distributed from all confounders of the risk factor–outcome
association) and (c) that it has no conditional association with outcome (the genetic variant is
independently distributed from the outcome conditional on the confounders and the risk factor)
(49). These assumptions imply the exclusion-restriction condition—namely, if the risk factor and
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confounders are kept constant, then intervening on the genetic variant will have no impact on the
outcome (1). If the IV assumptions are satisfied, then the genetic variant can be treated like random
allocation to a treatment group in a randomized controlled trial (59). Any association between the
genetic variant and the outcome implies that the risk factor is a cause of the outcome in the same
way as an intention-to-treat effect implies the efficacy of the treatment in a randomized trial (41).
Under further parametric assumptions [sufficient conditions are that the relationships between
variables are linear and that genetic associations with the risk factor and outcome do not vary with
the confounder (i.e., no effect modification) (57)], a causal effect of the risk factor on the outcome
can be estimated.
2.3. Assessing the Instrumental Variable Assumptions
The IV assumptions are unlikely to be true for all genetic variants and require a genetic variant
to act like an unconfounded proxy measure of intervention on the risk factor. There are several
reasons why this may not be the case (38, 47, 94). For example, the genetic variant may be
pleiotropic—that is, it affects multiple risk factors on different causal pathways. Such a variant
would not provide any specific information about intervention on the risk factor under analysis.
Alternatively, a genetic variant may not directly affect the risk factor, but instead affect a precursor
of the risk factor. If there is only one causal pathway from the genetic variant to the outcome
and if this passes via the risk factor of interest, then the genetic variant would still be a valid
IV (18). However, if there is an alternative pathway from the precursor of the risk factor to the
outcome that does not pass via the risk factor, then again, the IV assumptions would be violated
and the causal status of the risk factor cannot be reliably assessed. Other ways in which the IV
assumptions may be violated have been well documented and include population stratification
(the population under investigation consists of multiple subpopulations, such as different ethnic
groups, meaning that genetic associations may reflect differences in allele frequencies among the
subpopulations and not true biological relationships) and linkage disequilibrium (LD) (the genetic
variant is correlated with another variant that influences a competing risk factor) (66).
The most straightforward way of assessing the IV assumptions is to test the association of
the genetic variant with a range of potential confounders (24). However, this approach is far
from foolproof. First, not all relevant confounders may be known or measured. Second, a genetic
association may reflect a downstream consequence of intervention on the risk factor itself and
not a pleiotropic effect (Figure 1). For example, variants in the IL1RN gene region linked with
interleukin-1 are also associated with CRP and interleukin-6 (62). However, pharmacological
intervention on the interleukin-1 receptor antagonist pathway via the drug anakinra also leads to
elevated CRP and interleukin-6 levels, suggesting that these associations may reflect mediation
along a single causal pathway (also known as vertical pleiotropy) rather than effects on multiple
causal pathways and hence pleiotropy (also known as horizontal pleiotropy). Third, there is a
a  Pleiotropy
Risk
factor 
b  Mediation
Genetic
variant
Risk factor
Covariate
Genetic
variant Covariate
Figure 1
(a) Diagram illustrating pleiotropy (horizontal pleiotropy). The genetic variant is separately associated with
the risk factor and covariate via different causal pathways. (b) Diagram illustrating mediation (vertical
pleiotropy). The genetic variant is directly associated with the risk factor, and the association with the
covariate is a downstream consequence of the risk factor.
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multiple testing problem—onewould not want to be overly conservative with testing for violations
of the IV assumptions, but if large numbers of potential confounders have been measured, then
some associations with the genetic variant may arise from chance alone.
Alternative ways of assessing the IV assumptions are (a) considering positive and negative
control variables (20, 72) (for example, CRP and interleukin-6may be considered positive controls
for intervention on interleukin-1); (b) subsetting the population, particularly if there are subsets
in the population that may have different distributions of the risk factor (for a fuller discussion,
see Section 3.9); and (c) performing cross-ethnic analyses (if a risk factor is a cause of an outcome,
then a causal effect should be evidenced across different populations, whereas patterns of LD and
population stratification will differ among populations).
2.4. Advantages and Disadvantages of Monogenic Analyses
Among all Mendelian randomization analyses, monogenic analyses include the most reliable as-
sessments of causal relationships. Particularly for protein risk factors, there is often a gene region
that encodes either the risk factor itself or a biologically relevant factor in the causal pathway relat-
ing to the risk factor (such as the interleukin-1 receptor antagonist for interleukin-1). These gene
regions have the greatest plausibility for having specific associations with these risk factors and for
being reliable proxies to assess the effect of intervening on the same pathway by which the variant
acts. Such investigations are also of the most value to developers of pharmaceutical agents, as the
genetic variant often highlights a pathway that can be targeted by pharmacological intervention
(79). Loss-of-function mutations represent potential candidate variants for monogenicMendelian
randomization investigations. However, care must be taken in the interpretation of findings (par-
ticularly quantitative findings) in this case; a loss-of-function mutation is unlikely to be a good
proxy for a clinical or pharmacological intervention on the risk factor, as such interventions are
unlikely to change protein function.
However, there is a sense in which performing a monogenicMendelian randomization analysis
(which is essentially a candidate gene study) is to put all of one’s eggs into a single basket.Of course,
it is necessary to put the eggs into some basket, and in many cases it is better to put the eggs into
a single reliable basket rather than several unreliable baskets. For example, multiple gene regions
have been discovered that are associatedwithCRPat a genome-wide level of statistical significance,
and it would be possible to conduct Mendelian randomization analyses using each of these genetic
variants. However, for some of these gene regions (such as IL6R), the allele that is associated with
increased CRP is associated with increased CHD risk, and for other gene regions (such asAPOC1,
LEPR, andHNF2), the CRP-increasing allele is associated with decreased CHD risk (16). Clearly,
CRP cannot simultaneously be both protective and harmful for CHD risk. In truth, it is difficult to
justify looking beyond the CRP gene region to assess the specific causal role of CRP. However, in
other cases, combining data frommultiple genetic variants associated with a single risk factor may
provide convincing evidence that the risk factor is causal even when the IV assumptions cannot
be clearly justified for any one variant.
3. POLYGENIC ANALYSES: THE DIFFICULT CASE
Polygenic risk factors—risk factors that have multiple genetic determinants—include biomarkers
that aremore complex thanproteins, such as low-density lipoprotein (LDL) cholesterol; exogenous
biomarkers, such as calcium; andmore complexmultifactorialmeasures, such as blood pressure and
body mass index (BMI). Mendelian randomization analyses for such risk factors are intrinsically
more complex, as they must synthesize evidence from multiple genetic variants.
www.annualreviews.org • Causal Relationships from GWAS Data 307
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Figure 2
(a) Genetic associations with risk factor and outcome (coronary heart disease risk) for eight genetic variants that have biological links to
low-density lipoprotein (LDL) cholesterol. The blue lines are 95% confidence intervals for the genetic associations (all associations are
oriented to the LDL cholesterol–increasing allele); the vertical axis is plotted on a log scale. (b) Variant-specific causal estimates (odds
ratio for coronary heart disease per 1-mmol/L increase in LDL cholesterol) from the ratio method for eight variants. The solid blue
lines are 95% confidence intervals for the causal estimates; the dashed blue line is the inverse-variance weighted estimate.
3.1. Example: Low-Density Lipoprotein Cholesterol and Coronary
Heart Disease Risk
The clearest example of a plausible Mendelian randomization analysis for a polygenic risk factor
is for LDL cholesterol and CHD risk. Several gene regions contain candidate IVs for LDL
cholesterol; some encode a compound that is biologically relevant to LDL cholesterol, whereas
others represent proxies for an existing or proposed LDL cholesterol–lowering drug.
Figure 2a shows genetic associations with CHD risk (OR per LDL cholesterol–increasing
allele) taken from the CARDIoGRAMplusC4D Consortium (33) plotted against genetic associa-
tions with LDL cholesterol (per-allele changes in LDL cholesterol) taken from the Global Lipids
GeneticsConsortium for eight genetic variants in different gene regions (46).Not only are all of the
LDL cholesterol–increasing alleles concordantly associated with increased CHD risk, but there is
remarkable consistency in the causal estimates (Figure 2b). The gradient of the line from the ori-
gin to each point is equal to the causal estimate (assumed to be linear on the logOR scale) based on
the corresponding genetic variant; this is known as the ratio estimate and represents the change in
the outcome per unit change in the risk factor. Even though each variant affects LDL cholesterol
via a different biological mechanism, the increase in CHD risk seems to depend only on the mag-
nitude of change in LDL cholesterol. This consistency in the causal estimate has been observed to
extend even to rare variants that have much larger genetic associations with LDL cholesterol (44).
Generally speaking, if multiple genetic variants in different gene regions all show the same
direction of association with the outcome, then a causal relationship is plausible, particularly if the
causal estimates based on the individual variants are all similar. As a corollary, if the causal estimates
of several genetic variants are all similar, but there is one variant whose estimate differs sharply,
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Figure 3
(a) Genetic associations with risk factor and outcome (type 2 diabetes risk) for eight genetic variants that have biological links to
low-density lipoprotein (LDL) cholesterol. The blue lines are 95% confidence intervals for the genetic associations (all associations are
oriented to the LDL cholesterol–increasing allele); the vertical axis is plotted on a log scale. (b) Variant-specific causal estimates (odds
ratio for type 2 diabetes per 1-mmol/L increase in LDL cholesterol) from the ratio method for eight variants. The solid blue lines are
95% confidence intervals for the causal estimates; the dashed blue line is the inverse-variance weighted estimate.
then this genetic variant may be pleiotropic. However, it would seem unwise to make judgments
about the validity of a genetic variant as an IV based solely on its associations with no reference
to biological knowledge about the function of the variant; it is possible that the homogeneous
variants are the invalid ones, or that the outlying variant provides important information relating
to the question of causation.
3.2. More Complex Examples
As an example in which causal inferences are less clear, we consider associations of the same eight
LDL cholesterol–related genetic variants with risk of type 2 diabetes taken from the DIAGRAM
Consortium (40). For seven of the eight variants, the LDL cholesterol–increasing allele is asso-
ciated with a decrease in the risk of type 2 diabetes (Figure 3a). The exception is the variant
in the APOB locus. Even among those variants suggesting a protective effect of increased LDL
cholesterol, the variant-specific causal estimates were not consistent in magnitude (Figure 3b),
suggesting either mechanism-specific effects or that the effect of LDL cholesterol on type 2 dia-
betes risk also depends on particle size or some other aspect of lipid-related biology (73).
As examples in which causal inferences are even less clear, we consider Mendelian random-
ization analyses for high-density lipoprotein (HDL) cholesterol and CHD risk (Figure 4a), and
LDL cholesterol and Alzheimer’s disease risk (Figure 4b). Both of the analyses include all variants
previously associated with the lipid fraction risk factor at a genome-wide level of statistical signif-
icance ( p < 5× 10−8) in the Global Lipids Genetic Consortium data (46). For HDL cholesterol,
this is because there are few if any variants that have specific associations with HDL cholesterol
www.annualreviews.org • Causal Relationships from GWAS Data 309
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Figure 4
(a) Genetic associations with risk factor [high-density lipoprotein (HDL) cholesterol] and outcome (coronary heart disease risk) for 86
genetic variants. The blue lines are 95% confidence intervals for the genetic associations (all associations are oriented to the HDL
cholesterol–increasing allele). (b) Genetic associations with risk factor [low-density lipoprotein (LDL) cholesterol] and outcome
(Alzheimer’s disease risk) for 76 genetic variants. The blue lines are 95% confidence intervals for the genetic associations (all
associations are oriented to the LDL cholesterol–increasing allele).
and are not also associated with other lipid fractions. In the first case, while genetic variants having
less strong associations with HDL cholesterol do seem to have protective associations on average
with CHD risk, variants having the strongest associations with HDL cholesterol do not also have
the strongest associations with CHD risk. In the second case, while two of the genetic variants that
are strongly associated with LDL cholesterol do have strong associations with Alzheimer’s disease,
none of the other variants are strongly associated with Alzheimer’s disease, and the association
estimates seem to be symmetrically distributed about the null. We return to these examples as we
introduce the various methods.
3.3. Two-Stage Least Squares and the Inverse-Variance Weighted Methods
To quantitatively combine evidence from multiple genetic variants, we estimate the causal effect
of the risk factor on the outcome. (The interpretation of this estimate is discussed in Section 5.)
With a single genetic variant, the causal estimate (known as the ratio estimate) is obtained by
dividing the beta coefficient for the association of the variant with the outcome (βˆY ) by the beta
coefficient for the association of the variant with the risk factor (βˆX ). When there are several
IVs, the most efficient assessment of causation in terms of statistical power is the two-stage least
squares method (100, chap. 15). This is undertaken by first regressing the risk factor on the genetic
variants and then regressing the outcome on fitted values of the risk factor from the first-stage
regression (3). When only summarized data on the per-allele genetic associations with risk factor
and outcome are available, the same estimate can be obtained by the inverse-variance weighted
method, which combines the association estimates (beta coefficients and standard errors) into a
single estimate of the causal effect (22). This can be implemented by inverse-variance weighted
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meta-analysis of the ratio estimates from each genetic variant (19). Equivalently, the same estimate
can be obtained from weighted linear regression of the genetic associations with the outcome (βˆYj
for genetic variant j) on the genetic associations with the risk factor (βˆXj), using the reciprocals of
the variances of the genetic associations with the outcome [se(βˆYj)−2] as weights:
βˆYj = θ βˆXj + j, j ∼ N [0, se(βˆYj)2], 1.
where θ is the causal effect parameter (92). If the genetic variants are correlated in their distribu-
tions, then these correlations should be accounted for in the regression model using generalized
weighted least squares regression (22).
The estimate from the two-stage least squares/inverse-variance weighted method is a weighted
mean of the ratio estimates based on the individual genetic variants, each of which is a consistent
estimate of the causal effect when the genetic variant is a valid IV. As such, the inverse-variance
weighted method generally provides a consistent estimator of the causal effect of the risk factor
on the outcome only if all the genetic variants are valid IVs, and is a biased estimate if one or more
of the variants is invalid.
We now consider different robust methods that can make reliable causal inferences under
weaker assumptions. A robust method for Mendelian randomization is one that does not require
all genetic variants to be valid IVs to give consistent estimates of a causal parameter (16). We
assume for simplicity that all the genetic variants are uncorrelated in their distributions; this is
usually achieved by including one genetic variant from each gene region in the analysis. We also
make linearity and homogeneity assumptions as discussed elsewhere (11), in particular that all
valid IVs estimate the same causal parameter (for further discussion of this point, see Section 5.1).
3.4. Median Estimation Methods
A conceptually straightforward method that provides consistent estimates under the assumption
that at least 50% of the genetic variants are valid instruments is the simple median method (8).
The median estimate is obtained by first calculating the ratio estimates based on each genetic
variant and then taking the median of these estimates. With an infinite sample size, the genetic
associations for each valid instrument should lie on a straight line through the origin. The gradient
of this line will be the true causal effect and will correspond to the median estimate provided that
at least half of the genetic variants are valid instruments (53). With a finite sample size, the simple
median estimate still provides a causal estimate that is supported by the majority of the genetic
variants. The median estimate is also not sensitive to genetic variants with outlying estimates—a
variant contributes in the same way to an analysis regardless of whether its estimate is slightly
above the median or far above it. A weighted median method has also been proposed that assigns
more weight in the analysis to genetic variants that have more precise ratio estimates (8).
3.5. Modal Estimation Methods
A related concept is a modal estimation method. With an infinite sample size, in the case that
exactly 50% of genetic variants estimate one value and 50% of the genetic variants estimate
another value, it would not be possible to determine which of those values is the true causal effect.
However, if the invalid genetic variants all estimate different values, then the true causal effect can
be identified even when fewer than 50% of the genetic variants are valid instruments (52). If the
largest group of genetic variants with the same causal estimate are the valid instruments [referred
to by Hartwig et al. (54) as the zero modal pleiotropy assumption], then with an infinite sample
size, the modal variant-specific ratio estimate would be the true causal effect.
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With finite data, no two estimates would be exactly the same, so a modal estimate cannot
be considered directly. Hartwig et al. (54) considered a kernel-density-smoothed estimate of the
distribution of the variant-specific causal estimates (the ratio estimates) and took the maximum of
this distribution as their modal causal estimate. Burgess et al. (31) considered a model averaging
procedure that gives a mixture distribution based on the causal estimates from each subset of
variants and takes the maximum of this distribution as the modal causal estimate. The model
averaging procedure has several technical advantages over the kernel-smoothed approach in that
it is asymptotically efficient, does not require the specification of a bandwidth parameter, and allows
for uncertainty in determining which peak is the global maximum in its confidence interval. As
a consequence, the method is able to identify the presence of multiple subsets of variants with
similar causal estimates, suggesting the existence of multiple causal mechanisms by which the risk
factor influences the outcome.
3.6. Regularization Methods
A further class of methods invoking a similar assumption for consistent estimation (that is, some
variants are valid IVs, but we do not know which ones) uses regularization to identify valid IVs.
Regularization is the use of an external condition to fit a statistical model when there are more
parameters than data points. Kang et al. (65) considered a statistical model in which genetic
variants influence an outcome variable not only via their associations with a risk factor but also via
direct (pleiotropic) effects on the outcome. These effects cannot all be identified, as the number of
parameters is equal to the number of genetic variants plus one (one pleiotropic effect parameter for
each variant plus the causal effect parameter). To provide identification, they use L1 penalization
(also known as the lasso) with a tuning parameter to control the total of the absolute values of all
the pleiotropic effects. A related method using an adaptive lasso was considered by Windmeijer
et al. (99).We here describe a simple implementation of this approach with summarized data (15).
The inverse-variance weighted method (Equation 1) minimizes the weighted sum of squares:
θˆIVW = arg min
θ
∑
j
se(βˆYj)−2(βˆYj − θ βˆXj)2. 2.
We propose adding a separate term, θ0 j , for each genetic variant that can be interpreted as the
pleiotropic effect of variant j. If the term is equal to zero, this implies that the variant is a valid IV.
For identification, we add an L1-penalty term:
θˆLASSO,λ = arg min
θ
⎡
⎣∑
j
se(βˆYj)
−2
(βˆYj − θ0 j − θL βˆXj)2 + λ
∑
j
|θ0 j |
⎤
⎦ , 3.
where λ is a tuning parameter and θL is the causal parameter.When λ is set to zero, the parameters
are not identified; when λ is tends to infinity, the inverse-variance weighted estimate is recovered.
By considering estimates of the causal effect θˆLASSO,λ across a range of values for λ, we can compare
causal inferences based on different numbers of genetic variants, with other variants being allowed
to have pleiotropic effects.
Alternatively, Bayesian methods to analyze the same statistical model have been developed.
These approaches use a prior for formal identification of the statistical model and to force the
pleiotropic effects θ0 j to take values close to zero unless there is strong evidence of pleiotropy.
Methods have been proposed using a horseshoe prior (6) and a spike-and-slab prior (70).
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3.7. The MR-Egger Method
The MR-Egger method (7) was the first robust method for Mendelian randomization to become
widely used and has become the de facto sensitivity analysis of choice inmany people’s minds. This
is somewhat unfortunate, as the assumption required for the method to give consistent estimates
and valid causal inferences is not always plausible, and the MR-Egger method is quite fragile to
departures from this assumption, as well as being sensitive to influential points in the regression
model (30), having low power in many cases (9) and being subject to more severe weak instrument
bias than other IV methods in a one-sample setting (55). However, in its defense, the MR-Egger
method allows all genetic variants to be invalid IVs provided that they satisfy a different untestable
assumption. Also, it is valuable to consider alternative assumptions for causal inference rather than
multiple assumptions that are different flavors of “some genetic variants are valid instruments.”
In the MR-Egger method, we fit a regression model similar to that for the inverse-variance
weighted method, but with an intercept term θ0:
βˆYj = θ0 + θE βˆXj + j, j ∼ N [0, se(βˆYj)2]. 4.
The intercept term is similar to the pleiotropic effect parameters in Equation 3, except that there
is a single pleiotropy term θ0 rather than a separate term for each genetic variant. This term
represents the average pleiotropic effect of a genetic variant (the expected association of a variant
with the outcome if its association with the exposure is zero) (9). If all the genetic variants are valid
instruments, then this term should tend to zero asymptotically. Indeed, rejection of the statistical
test that this term equals zero (known as directional pleiotropy) implies that the inverse-variance
weighted estimate is biased (30). This is the MR-Egger intercept test. It provides a valuable test
of the validity of the set of genetic variants as IVs.
Additionally, if the genetic variants satisfy a condition known as the instrument strength
independent of direct effect (InSIDE) assumption, then the MR-Egger slope estimate is a consis-
tent estimate of the causal effect even if there is directional pleiotropy (7). The genetic associations
with the outcome can be decomposed into an indirect component via the risk factor and a direct
(pleiotropic) component:
βYj = θ βXj + αj. 5.
The InSIDE assumption states that the pleiotropic effects of genetic variants (α j ) are indepen-
dently distributed from the genetic associations with the risk factor (βXj). This assumption would
be plausible if pleiotropic effects of genetic variants were to act directly on the outcome via mech-
anisms unassociated with the risk factor or confounders of the risk factor–outcome association,
but it is less plausible when pleiotropic effects act via related pathways or via confounders (30).
The InSIDE assumption is not testable, and violation of the assumption can lead to anomalous
results [for example, the estimated average pleiotropic effect can be larger than the associations
of all variants with the outcome (67)—an implausible situation]. Hence, while the MR-Egger
method is useful, particularly for detecting pleiotropy via the intercept test, it should not be relied
on as a primary analysis method, and its findings should be weighed carefully (particularly when
they differ sharply from estimates from other methods), for example, by judging whether they are
particularly influenced by a single observation.
For the example of HDL cholesterol and CHD risk (Figure 4a), the straightforward inverse-
variance method that assumes all genetic variants are valid instruments suggests that HDL choles-
terol is causally protective of CHD, with an odds ratio estimate of 0.85 (95% CI= 0.76–0.95) per
1 standard deviation increase in HDL cholesterol. By contrast, the weighted median method gives
OR= 0.95 (95% CI= 0.87–1.05), and the MR-Egger method gives OR= 1.10 (95% CI= 0.93–
1.31) with an intercept term that differs from zero ( p= 0.0004), suggesting no evidence for a causal
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relationship. All three methods agree that LDL cholesterol is a harmful risk factor for CHD risk,
even when all of its genome-wide significant predictors are used in the analysis (20).
3.8. Multivariable Methods
Multivariable Mendelian randomization (29) is an alternative approach for causal inference that
can be used when it is difficult to find genetic variants specifically and uniquely associated with
particular risk factors but it is possible to find genetic variants specifically associated with a set
of risk factors. For example, it is difficult to find genetic variants that are associated with HDL
cholesterol but not also associated with LDL cholesterol and triglycerides (23). In multivariable
Mendelian randomization, genetic variants are allowed to be associated with multiple measured
risk factors, so long as they are not associated with confounders of any of the risk factor–outcome
associations and do not directly affect the outcome—any genetic association with the outcome is
mediated via one or more of the risk factors.
We assume that summarized data are available on the associations of genetic variants with each
risk factor in turn (βˆXj1, βˆXj2, . . . , βˆXjK for each variant j). The inverse-variance weighted method
can be extended to a multivariable weighted regression model:
βˆYj = θ1βˆXj1 + θ2βˆXj2 + · · · + θK βˆXjK + j,  j ∼ N [0, se(βˆYj)2]. 6.
The parameters θ1, θ2, . . . , θK represent the direct causal effects of each risk factor in turn on the
outcome (the effect of varying the corresponding risk factor while keeping all other risk factors
fixed). Whereas the MR-Egger method allows for unmeasured pleiotropic effects, multivariable
Mendelian randomization assumes that all pleiotropic effects are measured and accounted for.
These methods can be combined into a multivariable MR-Egger method that accounts for both
measured and unmeasured pleiotropy (under the InSIDE assumption) by including an intercept
term in Equation 6 (80).
Multivariable Mendelian randomization can also be used to consider problems of mediation in
order to unravel complex etiological pathways (25). It has been used to demonstrate that the causal
effect of age at menarche on breast cancer risk can be decomposed into a harmful indirect effect
via decreased BMI and a protective direct effect not via BMI (39). Another area of application in
which this method can be used is when there are multiple biomarkers influenced by several genetic
variants in a single region. For example, multivariable Mendelian randomization suggested that
genetic associationswith atopic dermatitis of variants in the IL1RL1–IL18R1 locus on chromosome
2 are driven by IL18R1 and IL1RL2 rather than by IL1RL1 (87).
3.9. Interactions and Subsetting
Another approach for assessing the validity of causal inferences is exploiting subsets within the data
set. For example, in East Asian societies, women tend not to drink alcohol for cultural reasons.
Hence, if alcohol is a cause of a disease outcome, then genetic variants that influence alcohol
metabolism should be associated with the outcome in men but not in women, as there is no
mechanism by which the genetic variants would affect the outcome in individuals who have zero
exposure to alcohol (34). If the same genetic associations with the outcome were present in both
men and women, this would suggest that they are driven not by alcohol consumption, but rather
by a pleiotropic mechanism (93).
Additionally, stronger genetic associations with esophageal cancer risk have been observed in
populations that drink heavily, and no association has been observed in men who abstain from
alcohol (69). Some care is needed here, as the decision to abstain from alcohol is self-determined,
and hence conditioning on abstinence may lead to selection bias (56). However, in this case the
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differences between the genetic associations in drinkers and nondrinkers are so extreme that it is
highly unlikely that they are explained by selection bias alone. The conditions that the subsets
must satisfy have been provided; ideally, the genetic associations with the risk factor should be
present in one subset but not in the other, but any pleiotropic effects of the genetic variants should
be identical across subsets (93).
This idea has been extended to interactions with a continuous variable under the name Slichter
regression (84). Similar conditions are required—genetic associations with the risk factor should
depend on the interacting variable, but any pleiotropic effects should not be subject tomodification
by the interacting variable.
3.10. Practical Advice
In practice, we would encourage investigators to plot the genetic associations with the risk factor
against those with the outcome (as in Figures 2a, 3a, and 4a,b) as a routine part of polygenic
Mendelian randomization investigations. This provides a visual check for heterogeneity and en-
ables both investigators and readers to judge whether there is general consistency in genetic
associations and whether any claimed causal effect is evidenced by all of the genetic variants or
just a subset of them. Formal tests for heterogeneity are also available (10, 48). Other plots that
have been suggested for investigating pleiotropy include forest plots (68) and funnel plots (86),
taken from the meta-analysis literature.
While we have presented a long list of robust methods forMendelian randomization, we would
not expect every Mendelian randomization investigation to include all of these analyses. Indeed,
we would encourage investigators to think carefully about which sensitivity analyses would be
most appropriate given their particular investigation. For example, if there are genetic variants
that are likely to be outliers or influential points (such as variants in the APOE gene region for
Alzheimer’s disease or in the FTO gene region for BMI), then an outlier-robust approach may be
more appropriate than the MR-Egger method.
As an example of how robust methods can reveal inconsistencies in a Mendelian random-
ization investigation, we consider the investigation into the causal effect of LDL cholesterol on
Alzheimer’s disease using 380 genetic variants reported by Benn et al. (4). Causal estimates repre-
sent ORs per 1-mmol/L decrease in LDL cholesterol. The authors initially reported a highly sig-
nificant association based on the inverse-variance weighted method (OR= 0.83, 95% CI= 0.75–
0.92) and the MR-Egger method (OR= 0.64, 95% CI= 0.52–0.79). However, the funnel plot
of the variant-specific causal estimates plotted against their precisions revealed variants with ex-
treme outlying causal estimates, and the weighted median method gave a much different estimate
(OR= 0.97, 95% CI= 0.91–1.02). Further investigation showed that the variants suggesting a
strong causal effect were all located in and around the APOE gene region, a known risk factor
for Alzheimer’s disease (note that the two variants strongly associated with Alzheimer’s disease
in Figure 4b are both in the APOE gene region). Analyses excluding these variants suggested no
causal effect in either the inverse-variance weighted method (OR= 0.98, 95% CI= 0.93–1.03) or
the MR-Egger method (OR= 0.98, 95% CI= 0.87–1.09) (4; see the “rapid response” written by
the authors).
4. OTHER APPROACHES FOR INVESTIGATING RELATIONSHIPS
BETWEEN TRAITS WITH GENOME-WIDE ASSOCIATION
STUDY DATA
Mendelian randomization is not the only methodological approach for considering relationships
between risk factors and outcomes using genetic data, although it is the only approach that directly
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assesses the causal effect of a risk factor on an outcome. Other approaches include colocalization
and LD score regression.
4.1. Fine Mapping and Colocalization
Finemapping is a statistical approach to find genetic variants that causally affect a trait (5).We note
that a causal genetic variant is not required in a Mendelian randomization investigation—the first
IV assumption only requires a genetic variant to divide the population into groups with different
average levels of the risk factor (57).
Colocalization methods take a single region of the chromosome that is associated with two
traits and ask whether the same genetic variants are driving the associations with both traits (82).
As such, it is an extension of fine mapping to multiple traits. If the same genetic variants (or
variant) that give rise to the association with trait A also give rise to the association with trait B,
then the same biological mechanism is likely to be responsible for both associations. This does
not necessarily mean that trait A causes trait B (or vice versa), as it may be that a trait C causes
both A and B. However, even in this case, colocalization implies a shared etiology between traits
A and B.
As an example, colocalization showed that a genome-wide association study hit in the CTSH
gene region drove genetic associations with both type 1 diabetes and narcolepsy (50). The same
variant was also associated with gene expression but localized to monocytes and not to B cells.
These results demonstrate the utility of genetic association data for highlighting causal cell types
and potential druggable mechanisms.
Figure 5 illustrates differences between the assumptions made in Mendelian randomization
and in colocalization. In some cases, the statistical methodology used in the two approaches will be
identical (97); differences in the conclusions (for example, concluding that a risk factor is a cause
of the outcome) are conceptual and arise solely from different prior assumptions.
Colocalization methods are useful when a particular section of the chromosome has multiple
genes in close proximity (45, 60). It may be that genetic variants that are associated with a risk
factor also show an association with a disease outcome. This would lead to a positive finding in a
Mendelian randomization analysis. However, if the colocalization analysis showed that the peaks
of the associations were being driven by different variants, then this would suggest that the risk
factor is not the relevant causal agent. This could result from LD between two functional variants.
It could also be that the relevant measure of the risk factor has not been identified (for example,
suppose that the risk factor is not LDL cholesterol concentration but rather a measure of LDL
particle size).
Overall, colocalization focuses on a different causal question than does Mendelian randomiza-
tion, one that focuses on a single gene region rather than considering the totality of evidence for
Trait A
Trait B
Risk
factor
Genetic
variant
Genetic
variantOutcome
a  Mendelian randomization b  Colocalization
Figure 5
Schematic diagrams illustrating different assumptions made in (a) Mendelian randomization (in which the
genetic variant is assumed to associate directly with the risk factor and with the outcome only via the risk
factor) and (b) colocalization (in which the genetic variant is allowed to associate with both traits directly, and
causal effects may occur between the traits in either direction or not at all).
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a relationship between a risk factor and an outcome across multiple gene regions. However, the
more detailed interrogation of a single gene region performed in the colocalization method can
provide additional evidence to link a risk factor to an outcome. Colocalization can also be per-
formed between two disease outcomes, to assess whether the diseases have a common etiological
link even in the absence of a hypothesized mechanism or risk factor for that link.
4.2. Linkage Disequilibrium Score Regression
There are two forms of LD score regression: with a single trait (14) and with a pair of traits (13).
The aim of the method is to provide estimates of heritability (shared heritability for two traits)
that are unaffected by population stratification. Both approaches make use of LD scores. These
are obtained for each variant in turn by taking a window about the target variant, calculating the
squared correlation for each variant in this window with the target variant, and summing these
squared correlations. A genetic variant with a high LD score is a variant with a high degree of
“friendliness”—it has many nearby variants in high LD with it. If biologically relevant genetic
variants are uniformly distributed across the whole genome, then a genetic variant with a high
LD score is more likely to be correlated with a biologically relevant variant and hence is more
likely to be associated with phenotypic traits, including risk factors and outcomes. By contrast,
genetic variants that are subject to population stratification would not be more or less likely to
have high LD scores, so any genetic associations resulting from population stratification would
be independent of LD score.
With a single trait, LD score regression is implemented by regression of the chi-squared statis-
tics for the genetic associations with the trait against the LD scores for genetic variants across the
whole genome (14). The intercept term is interpreted as confounding (although by “confounding,”
the authors are referring to population stratification and cryptic relatedness between individuals
rather than conventional epidemiological confounding), and the slope coefficient is interpreted as
a revised estimate of heritability (narrow-sense heritability) that excludes population stratification.
Weights are used in the regression model to correct for correlations between variants and for the
varying precisions of the chi-squared statistics. With two traits, cross-trait LD score regression is
implemented by multiplying the z statistic for the genetic association with trait 1 by the z statistic
for the genetic association with trait 2 and then regressing this product of statistics against the
LD scores (13). The slope coefficient (representing shared heritability or genetic correlation) is
large when the same genetic variants predict both of the traits. Regression on the LD score should
ensure that estimates of heritability are driven by biologically relevant variants rather than variants
subject to population stratification. However, an implicit assumption in the method that variants
contribute equally to heritability estimates may be violated in realistic settings, leading to bias and
incorrect standard errors (83).
LD score regression differs from Mendelian randomization in several ways. First, LD score
regression is not only a polygenicmethod but amassively polygenicmethod, using genetic variants
from the whole genome. Second, LD score regression is symmetric in its two traits, whereas
Mendelian randomization assesses the effect of the risk factor on the outcome. It does not seek to
model one trait as a function of the other but rather uses the LD score as the dependent variable
in the regression model.
However, there are also connections between the approaches. In the MR-Egger method, the
intercept term in the regression model is viewed as a nuisance parameter relating to the degree
of pleiotropy, and the slope parameter is an estimate of the causal effect. In LD score regression,
the intercept term is again a nuisance parameter, and the slope parameter is of interest. This
suggests that a version of the InSIDE assumption is required by the LD score regression paper
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(no correlation between the residual terms in theLD score regression equation and theLD scores).
The problem of low power in the MR-Egger method can be sidestepped in cross-trait LD score
regression by specifying rather than estimating the intercept term.
A criticism of LD score regression is that every analysis for each pair of traits uses the same
LD scores as the dependent variable in the regression model (and as LD scores have been pre-
computed by its proponents, literally the same LD scores are used in the majority of applied
analyses). This means that any influential points in the regression will affect not only one LD
score regression analysis but all such analyses. LD scores are also likely to be a weak instrument in
the language of Mendelian randomization, as they will explain only a small proportion of variance
in the dependent variable. Additionally, owing to the scale of the data, it is not possible to provide
a visual representation of an LD score regression analysis. Standard regression diagnostics are
rarely, if ever, performed. Finally, results from LD score regression are not always consistent
with known causal relationships; for example, the method did not find evidence for a genetic
correlation between LDL cholesterol and CHD risk that survived a multiple testing correction
(13). The method has utility in mapping the genetic distance between related phenotypes, such
as determining how closely related different psychiatric disorders are in terms of their genetic
predictors (36). However, the reliance of the method on numerous linearity and independence
assumptions, incorrect weighting in the linear regression model (correct weights would require
computation of the Cholesky decomposition of a matrix with dimension equal to the number of
genetic variants in the model—misspecified weights are recommended for use in practice), and a
lack of validation against known causal relationships mean that results from the method should
not be treated too seriously as an assessment of causality.
5. THE RELEVANCE OF CAUSAL INFERENCES AND ESTIMATES
FROMMENDELIAN RANDOMIZATION
While Mendelian randomization aims to address the question of whether a risk factor is a cause of
an outcome, in reality this is not a well-defined question. For example, in answering the question
“Would lowering BMI reduce cardiovascular mortality?” several further questions arise: How is
BMI proposed to be lowered? By increasing metabolism? By suppressing appetite? How long
is BMI proposed to be lowered for? To whom will the intervention be applied? To answer the
question “Is high BMI a cause of increased cardiovascular mortality?” one must first pose the
question in a precise way.
A Mendelian randomization investigation compares subgroups in the population defined by
their genetic variants. As such, it is analogous to a randomized controlled trial, but one in which
the allocation to a “treatment group” is determined at conception. In a randomized trial, typically
the treatment that is assessed in the trial is also the one that is offered to patients. However, in
Mendelian randomization, the intervention that is assessed is changing an individual’s genotype at
conception, whereas the proposed treatment is to change the value of the risk factor by a different
mechanism (that is, not by altering their genes) and at a later time (usually in adulthood) (88). As
such, Mendelian randomization estimates (and, equivalently, assessments of causal relationships)
typically represent the impact of a long-term (or even lifelong) intervention in the risk factor by a
small amount in a primary prevention context (17). In many cases, the Mendelian randomization
investigation does address a relevant causal question. For example, one may be interested in
whether a CRP-reducing agent should be included in a polypill that is taken every day to reduce
mortality risk in healthy individuals. However, a Mendelian randomization investigation would
be less relevant for judging whether short-term highly elevated CRP levels should be targeted for
intervention in individuals displaying acute coronary symptoms.
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5.1. Heterogeneity and Pleiotropy
For a complex multifactorial risk factor such as BMI, there are many mechanisms by which the
risk factor could be lowered and many genetic variants associated with BMI that influence the
risk factor via different biological pathways. It is therefore entirely possible that some, but not
all, genetic variants associated with the risk factor are also associated with the outcome, or that
all variants are associated with the outcome but the causal effects estimated by different variants
differ. This is both a blessing and a curse for Mendelian randomization. On the positive side, this
can be used to identify which aspects of a complex risk factor influence an outcome and hence
may help identify effective mechanisms for reducing disease risk (98). On the negative side, the
methods above rely on homogeneity of the causal estimates based on different genetic variants
and interpret deviation from this as pleiotropy.
Even if there is heterogeneity in causal estimates, the ratio estimate based on each genetic
variant is still a valid test of the causal null hypothesis (that is, under the IV assumptions, it will
only differ from zero if the risk factor is a cause of the outcome) (22). Hence, the inverse-variance
weighted method still provides a valid test of the causal null hypothesis, as do the median-based
and mode-based methods. However, other methods, such as MR-Egger, are more sensitive to
these parametric assumptions. One practical solution is the recommendation to use random-
effects models in estimation, as these models translate heterogeneity between variant-specific
causal estimates into wider confidence intervals (11). Heterogeneous points should be investigated
carefully to assess whether there is any difference in how the genetic variant influences the risk
factor that may give rise to the heterogeneity or whether it is likely to be a result of pleiotropy.
5.2. Time-Dependent Causal Effects
Somemethodological development has been undertaken to try to perform IV analysis with a time-
to-event outcome (74, 91). While it is possible to assess the causal null hypothesis with a time-to-
event outcome [by assessing the association between the genetic variant(s) and outcome], any causal
estimates are unlikely to be reliable. Indeed, it would seem to be impossible to make any detailed
judgment about the timing of causal effects using genetic variants, unless one had specific temporal
knowledge about the action of the genetic variants on the risk factor. For example, if increased BMI
leads to increased cardiovascular mortality, then associations of genetic variants would be identical
if increased childhood BMI led to increased cardiovascular mortality, or if the causal risk factor
were instead increased adolescent BMI or increased BMI in early adulthood—assuming that the
genetic variant is associated with increased BMI for the whole life course. These scenarios could
be distinguished only by identifying and comparing associations for particular genetic variants
that increase BMI in childhood, those that increase BMI in adolescence, and so on.
Additionally, it is not possible (without additional information) to judge the viscosity of a risk
factor. By viscosity, wemean the rate at which changes in the risk factor will influence the outcome.
For instance, LDL cholesterol is likely to have high viscosity for CHD risk, as atherosclerosis is
a chronic condition resulting from long-term exposure to LDL cholesterol. Short-term inter-
ventions in LDL cholesterol would not be expected to lead to immediate reduction in CHD
risk. Indeed, increased time of exposure to LDL cholesterol–lowering drugs is associated with a
greater reduction in CHD risk per 1-mmol/L change in LDL cholesterol (89), with Mendelian
randomization estimates around two to three times greater in magnitude than even estimates of
risk reduction from randomized trials with five-year median follow-up (17). By contrast, blood
pressure may have lower viscosity as a risk factor, because although long-term exposure to high
blood pressure does lead to arterial stenosis, current blood pressure is likely to be an important
risk factor influencing CHD risk.
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This life-course perspective for genetic associations has positive consequences for Mendelian
randomization, as it means that genetic associations with disease outcomes may be greater than
one would expect from observational research, and hence the power to detect a causal relation-
ship may be greater than expected. However, it also means that causal estimates from Mendelian
randomization are not realistic guides to the impact of intervening on a risk factor in practice and
may be overly optimistic in general. Further research is needed to judge the similarity of obser-
vational epidemiological, clinical trial, and Mendelian randomization estimates in cases where all
are available.
6. ADDITIONAL STATISTICAL ISSUES IN MENDELIAN
RANDOMIZATION
AMendelian randomization investigation has two related aims: first, to assess whether a risk factor
has a causal effect on an outcome, and second, to estimate the magnitude of that causal effect. The
first aim is usually the primary one, with estimation being a secondary aim. As discussed above,
there are several reasons why a causal estimate obtained from Mendelian randomization is not
always a reliable guide to the expected impact of intervening on the same risk factor in practice. In
discussing statistical issues that may affect Mendelian randomization investigations beyond those
related to invalid instruments, we focus on biases that affect not only estimates but also the validity
of causal inferences, as these will lead to a greater-than-expected rate of false positive findings
from applied investigations. Here, we focus on sample overlap and collider bias.
6.1. Weak Instrument Bias and Sample Overlap
If the genetic associations with the risk factor and those with the outcome are estimated in separate
samples of the population, then the estimates will be independent. However, in practice, many
large international genetics consortia include the same studies and hence have participants in
common (71). This means that if genetic associations with the risk factor are overestimated, then
associations with the outcome will also tend to be overestimated (assuming that the risk factor and
outcome are positively correlated). This leads to weak instrument bias, a version of the winner’s
curse in IV analysis (26). In a two-sample analysis, independence between the association estimates
means that weak instrument bias is in the direction of the null and does not lead to inflated type 1
error rates. By contrast, in a one-sample analysis, bias is in the direction of the confounded
association and can lead to false positive findings (78). When there is some overlap between
the two data sets, bias is proportional to the degree of overlap (21). A weakness of summarized
data is that it is often not possible to determine the degree of sample overlap or to correct for
sample overlap by omitting individuals from the calculation of genetic association estimates or by
performing cross-validation (27).
6.2. Collider Bias
A collider is a variable that is a common effect of two variables (that is, it is causally downstream of
the two variables) (35). Even if the two variables are unrelated (they are marginally independent),
they will typically be related when conditioning on the collider (conditionally dependent). For
example, suppose that ear infections and throat infections are independent events. However,
conditional on an individual attending an ear, nose, and throat clinic, ear infections and throat
infections are conditionally dependent events—if an individual does not have an ear infection
but attends such a clinic, then it is more likely that the individual has a throat infection (77).
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Conditioning on a collider between an IV and confounder can induce an association between the
two even if they are marginally independent. This can lead to a valid IV becoming invalid and
hence to an association between the IV and the outcome in the absence of a causal effect of the
risk factor on the outcome. Intuitively speaking, even if a genetic variant can be treated as if it is
randomly distributed in the general population, it may not be randomly distributed in a subset of
the general population (in particular, in the sample population under investigation).
Collider bias can result fromdifferential selection into the sample population (56). For example,
if the sample is preferentially selected with respect to the risk factor or the outcome, then selection
bias (a form of collider bias) would occur (both the risk factor and the outcome are common effects
of the genetic variant and confounders, and hence both are colliders for these two variables). Col-
lider bias may also result from differential survival. If the risk factor affects survival, then selection
bias would also occur (95). This is particularly likely for Mendelian randomization investigations
of diseases of old age (75). It is also relevant for investigations of disease progression, as in order
to be included in an analysis of disease progression, one must have the disease in the first place.
A further situation where collider bias may occur is when the population under investigation is
stratified, in particular if the stratifying variable is downstream of the risk factor or outcome. A
Mendelian randomization analysis of the causal effect of BMI on breast cancer progression showed
that bias would occur if BMI were a cause of breast cancer risk (51). However, the magnitude of
the selection effect required to lead to substantial type 1 error inflation was greater than would
be plausibly expected, indicating that findings were likely to be robust to collider bias. A further
weakness of summarized data is that the analyst has no control over how the data were collected,
which studies were included in the case of consortium data, or what adjustment has been made
in calculating the genetic association estimates. Further research is needed to ascertain the ex-
tent to which collider bias is likely to be a practically relevant issue in Mendelian randomization
investigations.
7. CONCLUSION
This review has focused on answering two questions:When canMendelian randomization be used
tomake reliable causal inferences, andwhen can it be used tomake relevant causal inferences?As for
the first question, the most reliable causal inferences from Mendelian randomization will always
come from monogenic analyses (candidate gene Mendelian randomization), where the genetic
variant has a plausible biological link with the risk factor of interest. There are some issues with
these analyses, such as the problem of multiple testing. Additionally, the lessons of the candidate
gene era—the need for replication and stringent p-value thresholds (although perhaps not as strict
as a genome-wide threshold, since the number of comparisons is typically far lower)—must be
learned. While polygenic Mendelian randomization analyses have inherent weaknesses, as the IV
assumptions are unlikely to hold for all genetic predictors of a given risk factor, several methods
are available for interrogating the robustness of findings. Although the inverse-variance weighted
method will generally be the primary analysis method, all polygenic Mendelian randomization
investigations should atminimum assess the heterogeneity between causal estimates from different
variants, including a visual assessment via a scatter plot. Median-based and mode-based methods
are useful for determining whether a causal effect is evidenced by the majority of genetic variants
and for detecting multiple causal mechanisms within the genetic variants. In some cases, despite
its decreased power, the MR-Egger method will also be relevant for detecting pleiotropy (via
the intercept test) and for providing another estimate of the causal effect under a different set
of assumptions. In other scenarios, such as when there are influential points in the regression
model or when pleiotropic effects of multiple variants are likely to act via the same confounder,
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the MR-Egger method is less appropriate. Other approaches, such as multivariable Mendelian
randomization and interactions and subsetting, will be useful in some situations. Cases in which
multiple methods that make different assumptions lead to the same causal conclusion should be
given more evidential weight in favor of a causal relationship.
As for the second question, whileMendelian randomization addresses a relevant causal question
(that of the long-term effect of elevated levels of the risk factor on the outcome), it does not answer
all relevant causal questions. In addition, particularly for highly viscous risk factors, causal estimates
and even causal inferencesmay bemisleading guides to the impact of interventions on the same risk
factor in applied practice.While there is still much to learn from the emerging biobank era of data
sets whose main distinguishing feature is their sheer size, there are also many biologically relevant
questions about timings and mechanisms of causal effects that will require clever epidemiological
designs as well as clever statistical analyses—not all causal questions will be answerable simply by
increasing the sample size of cross-sectional data sets.
Future methodological questions to be determined include evaluating and comparing the var-
ious robust methods for Mendelian randomization, both those included in this review and further
proposed methods (2, 42, 64, 76, 90, 96). A related question is how to take advantage of genome-
wide genetic data, and even whether extensive genetic data will ever be useful for making reliable
causal inferences. An additional area is how large-scale data on multiple biomarkers and multiple
layers of -omics data can be used in Mendelian randomization investigations, particularly to learn
about complex etiological networks and causal mechanisms.
We look forward to the further development of genetic knowledge, statistical methodology,
and epidemiological data sets—active communication and close collaboration between these fields
have been defining features ofMendelian randomization research so far.Wehave every confidence
that this will continue.
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